Results 31 to 40 of about 249 (106)
New and emerging therapies in gout
Rheumatology &Autoimmunity, Volume 3, Issue 2, Page 70-77, June 2023., 2023 Evolution of gout therapy and newer drugs for gout. Abstract Gout is a disease that has been pestering humankind for centuries. Hence, gout therapeutics has always been a field of ongoing research. Beginning from colchicine, which was the first drug to come into use, to the latest inflammasome inhibitors and monoclonal antibodies, therapies for gout ...
Reeta James, Binoy J. Paul
wiley +1 more source
Uric acid transport, transporters, and their pharmacological targeting
Acta Physiologica, Volume 238, Issue 2, June 2023., 2023 Abstract Knowledge of uric acid (UA) crystallopathies preceded the identification of this compound. How the body handles and transports UA proved even more elusive. Over several decades, advances in molecular phenotyping have illuminated this hitherto nebulous field. Closely parallel to the characterization of the transport mechanisms of UA in the body
Emmanuel A. Adomako, Orson W. Moe
wiley +1 more source
Evidence-Based Complementary and Alternative Medicine, Volume 2022, Issue 1, 2022., 2022 Hyperuricemia is a common disease caused by a high level of uric acid. Urate transporter 1 (URAT1) is an important protein and mediates approximately 90% of uric acid reabsorption. Therefore, the URAT1 inhibitor is a class of uricosuric medicines widely used in the clinic for the treatment of hyperuricemia.
Qianghua Yuan +5 more
wiley +1 more source
Benzbromarone Inhibits Renal URAT1 and Attenuates Renal Damage in Streptozotocin-Induced Diabetic Rats, Independent of Its Uricosuric Effects. [PDF]
J Diabetes ResBackground Hyperuricemia remains a critical risk factor for diabetic kidney disease (DKD) currently. Recent studies have confirmed that allopurinol, an inhibitor of xanthine oxidase (XO), does not have any beneficial effects on DKD. However, it is still unclear how uricosurics, such as benzbromarone (BZ), affect the progression of DKD.
Chen C, Zhu P, Tan R, Liu Y, Ran J.
europepmc +2 more sources
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
British Journal of Pharmacology, Volume 178, Issue S1, Page S412-S513, October 2021., 2021 The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets ...
Stephen P H Alexander +24 more
wiley +1 more source
Efficacy and safety of dotinurad in hyperuricemic patients with or without gout: A systematic review and meta-analysis of randomized controlled trials [PDF]
, 2021 Introduction: A systematic review and meta-analysis of the available randomized controlled trials (RCTs) were conducted to investigate the efficacy and safety of dotinurad in hyperuricemic patients with or without gout.
Ali, Shajeea Arshad +8 more
core
Scientific Reports, 2021 Indoxyl sulfate (IS) accumulates in the body in chronic kidney disease (CKD). In the renal proximal tubules, IS excretion is mediated by OAT1/3 and ABCG2. These transporters are inhibited by some hypouricemic agents; OATs by probenecid and benzbromarone,
Tetsuya Taniguchi +7 more
doaj +1 more source
Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs
, 2021 Aims: We investigated sex and racial inequalities in clinical trials testing serum uric acid (SUA) lowering drugs and analyzed the temporal trends of participation among the pre-specified demographic groups.
Claudio Borghi +5 more
core +1 more source
, 2023 Introducere. Guta, una din cele mai vechi forme de artrită cunoscută din 2640 înainte de Hristos, descrisă de Hipocrate ca „boala de netrecut”, a cunoscut în ultimii 30 de ani o creștere cu 100% a prevalenței cu circa 41,2 milioane de adulți la nivel ...
Rakovskaia, Tatiana +2 more
core +1 more source